JP2004514412A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004514412A5 JP2004514412A5 JP2002500918A JP2002500918A JP2004514412A5 JP 2004514412 A5 JP2004514412 A5 JP 2004514412A5 JP 2002500918 A JP2002500918 A JP 2002500918A JP 2002500918 A JP2002500918 A JP 2002500918A JP 2004514412 A5 JP2004514412 A5 JP 2004514412A5
- Authority
- JP
- Japan
- Prior art keywords
- ligand
- host cell
- cell
- presenting
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003446 ligand Substances 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 8
- 230000002163 immunogen Effects 0.000 claims 6
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000012642 immune effector Substances 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20939100P | 2000-05-31 | 2000-05-31 | |
| US22625800P | 2000-08-17 | 2000-08-17 | |
| US25700800P | 2000-12-20 | 2000-12-20 | |
| PCT/US2001/017456 WO2001092307A2 (en) | 2000-05-31 | 2001-05-30 | Therapeutic compounds for ovarian cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004514412A JP2004514412A (ja) | 2004-05-20 |
| JP2004514412A5 true JP2004514412A5 (enExample) | 2005-02-17 |
Family
ID=27395361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002500918A Pending JP2004514412A (ja) | 2000-05-31 | 2001-05-30 | 卵巣癌のための治療化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20040138135A1 (enExample) |
| EP (1) | EP1355926A2 (enExample) |
| JP (1) | JP2004514412A (enExample) |
| AU (1) | AU2001265189A1 (enExample) |
| CA (1) | CA2410865A1 (enExample) |
| WO (1) | WO2001092307A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003050543A1 (en) * | 2001-12-05 | 2003-06-19 | Genzyme Corporation | Diagnosis of cancer using eif3 as a marker |
| FR2947716B1 (fr) * | 2009-07-10 | 2011-09-02 | Cormove | Implant prothetique ameliore |
| EP4072574A4 (en) * | 2019-12-11 | 2024-09-11 | Myeloid Therapeutics, Inc. | THERAPEUTIC CELL COMPOSITIONS AND METHODS OF PRODUCTION AND METHODS OF USE THEREOF |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5840839A (en) * | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| AU712820B2 (en) * | 1996-03-19 | 1999-11-18 | University Of Virginia Patent Foundation | Peptides recognized by melanoma-specific A1-, A2- and A3-restricted cytotoxic lymphocytes, and uses therefor |
| US5789200A (en) * | 1996-10-31 | 1998-08-04 | Smithkline Beecham Corporation | Human ETS family member, ELF3 |
| AU767391B2 (en) * | 1998-10-05 | 2003-11-06 | Genzyme Corporation | Peptides related to an IGF-II-R epitope, polynucleotides encoding the peptides, and their use in immunomodulation |
| AU2001264764A1 (en) * | 2000-05-31 | 2001-12-11 | Genzyme Corporation | Therapeutic anti-melanoma compounds |
| DE60109922D1 (de) * | 2000-05-31 | 2005-05-12 | Genzyme Corp | Therapeutische verbindungen gegen eierstockkrebs |
-
2001
- 2001-05-30 CA CA002410865A patent/CA2410865A1/en not_active Abandoned
- 2001-05-30 US US09/870,216 patent/US20040138135A1/en not_active Abandoned
- 2001-05-30 EP EP01939697A patent/EP1355926A2/en not_active Withdrawn
- 2001-05-30 WO PCT/US2001/017456 patent/WO2001092307A2/en not_active Ceased
- 2001-05-30 JP JP2002500918A patent/JP2004514412A/ja active Pending
- 2001-05-30 AU AU2001265189A patent/AU2001265189A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006511196A5 (enExample) | ||
| WO2005037190A3 (en) | Multiplex vaccines | |
| JP2006514920A5 (enExample) | ||
| JP2004503217A5 (enExample) | ||
| JP2006020648A5 (enExample) | ||
| ATE494910T1 (de) | Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort | |
| JP2007538044A5 (enExample) | ||
| JP2013502918A5 (enExample) | ||
| HUP0004327A3 (en) | Fusion proteins containing human papilloma virus (hpv) proteins and immunological fusion partner with t-helper epitopes to the hpv antigen, as well as vaccine formulations for treatment and/or profilaxis of hpv induced lesions | |
| CN101745104B (zh) | 含有复合佐剂的结核亚单位疫苗 | |
| JP2003519099A5 (enExample) | ||
| JP2002543769A5 (enExample) | ||
| JP2009515831A5 (enExample) | ||
| WO2000056360A3 (en) | Vaccine against antigens from bacteriae | |
| JP2007515393A5 (enExample) | ||
| BR0314373A (pt) | Produto imunogênico estável para a indução de anticorpos contra uma ou várias proteìnas antigênicas em um indivìduo, composições farmacêutica, imunogênica e de vacina e processo de preparação de um produto imunogênico | |
| EP2302059A8 (en) | Modifications of hiv Env, Gag, and Pol enhance immunogenicity for genetic immunization | |
| BR0010711A (pt) | Uso de moléculas co-estimulatórias solúveis para intensificar respostas imunes | |
| DK1267924T3 (da) | Immunterapeutiske metoder og sammensætninger | |
| JP2004510160A5 (enExample) | ||
| AU2002354806A1 (en) | Parathyroid hormone antibodies and related methods | |
| WO2003089584A3 (en) | Use of parapox b2l protein to modify immune responses to administered antigens | |
| Files et al. | Self-adjuvanting nanovaccines boost lung-resident CD4+ T cell immune responses in BCG-primed mice | |
| DE60234015D1 (de) | Latentes tuberkulose-diagnostisches antigen und verwendungsmethode | |
| JP2006515744A5 (enExample) |